Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Lyra Therapeutics (LYRA) EBITDA (2021 - 2025)

Lyra Therapeutics has reported EBITDA over the past 5 years, most recently at -$7.0 million for Q4 2025.

  • Quarterly results put EBITDA at -$7.0 million for Q4 2025, up 36.8% from a year ago — trailing twelve months through Dec 2025 was -$28.9 million (up 69.06% YoY), and the annual figure for FY2025 was -$28.9 million, up 69.06%.
  • EBITDA for Q4 2025 was -$7.0 million at Lyra Therapeutics, down from -$6.0 million in the prior quarter.
  • Over the last five years, EBITDA for LYRA hit a ceiling of -$6.0 million in Q3 2025 and a floor of -$48.2 million in Q2 2024.
  • Median EBITDA over the past 5 years was -$12.8 million (2021), compared with a mean of -$14.2 million.
  • Biggest five-year swings in EBITDA: crashed 208.07% in 2024 and later surged 84.56% in 2025.
  • Lyra Therapeutics' EBITDA stood at -$13.6 million in 2021, then fell by 4.47% to -$14.2 million in 2022, then dropped by 6.26% to -$15.1 million in 2023, then grew by 27.24% to -$11.0 million in 2024, then surged by 36.8% to -$7.0 million in 2025.
  • The last three reported values for EBITDA were -$7.0 million (Q4 2025), -$6.0 million (Q3 2025), and -$7.4 million (Q2 2025) per Business Quant data.